​

Incyte (INCY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INCY Stock Forecast

Incyte (INCY) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $95.38, with a high of $200.00 and a low of $60.00. This represents a 29.38% increase from the last price of $73.72.

$50 $80 $110 $140 $170 $200 High: $200 Avg: $95.38 Low: $60 Last Closed Price: $73.72

INCY Stock Rating

Incyte stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (66.67%), 7 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 7 14 0 Strong Sell Sell Hold Buy Strong Buy

INCY Forecast vs Benchmarks

TypeNameUpside
StockIncyte29.38%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--15
Avg Price Target--$81.93
Last Closing Price$73.72$73.72$73.72
Upside/Downside--11.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2521014-127
Dec, 2421014-127
Nov, 2451213-131
Oct, 24812131135
Sep, 24812131135
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2024Aaron KesslerSeaport Global$200.00$73.00173.97%171.30%
Oct 30, 2024Jay OlsonOppenheimer$82.00$73.6011.41%11.23%
Oct 30, 2024David LebowitzCitigroup$97.00$73.6031.79%31.58%
Oct 29, 2024Kelly ShiJefferies$84.00$73.6014.13%13.94%
Oct 29, 2024Tazeen AhmadBank of America Securities$90.00$73.6022.28%22.08%
Sep 30, 2024Andy ChenWolfe Research$84.00$66.1027.08%13.94%
Sep 16, 2024Tazeen AhmadBank of America Securities$68.00$63.566.99%-7.76%
Sep 16, 2024Salveen RichterGoldman Sachs$60.00$63.56-5.60%-18.61%
Aug 18, 2024David LebowitzCitigroup$92.00$62.1648.01%24.80%
Jul 31, 2024Brian AbrahamsRBC Capital$66.00$65.700.46%-10.47%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 19, 2024OppenheimerOutperformOutperformhold
Nov 19, 2024BMO CapitalUnderperformUnderperformhold
Oct 30, 2024Seaport GlobalBuyupgrade
Oct 30, 2024RBC CapitalSector PerformSector Performhold
Oct 30, 2024BMO CapitalUnderperformUnderperformhold
Oct 30, 2024CitigroupBuyBuyhold
Oct 29, 2024JefferiesBuyBuyhold
Oct 29, 2024Bank of America SecuritiesNeutralBuyupgrade
Oct 23, 2024Wells FargoSector PerformSector Performhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.36$4.30$1.53$2.67-----
Avg Forecast$-1.31$2.58$1.76$3.60$1.26$5.90$7.18$8.78$10.69
High Forecast$-1.41$2.47$1.65$3.50$1.01$4.97$5.47$6.71$10.10
Low Forecast$-1.26$2.76$1.86$3.70$1.53$6.91$9.31$11.60$11.43
Surprise %3.82%66.67%-13.07%-25.83%-----

Revenue Forecast

$2B $3B $4B $5B $6B $7B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.67B$2.99B$3.39B$3.70B-----
Avg Forecast$2.54B$2.92B$3.34B$3.69B$4.20B$4.64B$5.05B$5.46B$5.94B
High Forecast$2.45B$2.83B$3.18B$3.66B$4.13B$4.45B$5.01B$5.40B$5.70B
Low Forecast$2.67B$3.08B$3.49B$3.73B$4.25B$4.89B$5.10B$5.52B$6.26B
Surprise %5.07%2.12%1.69%0.18%-----

Net Income Forecast

$-5B $-3B $-2B $-200M $1B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-295.70M$948.58M$340.66M$597.60M-----
Avg Forecast$-4.06B$1.33B$1.45B$597.60M$287.16M$1.34B$1.26B$1.52B$2.41B
High Forecast$-5.00B$1.07B$1.16B$478.08M$228.42M$1.12B$1.24B$1.52B$2.28B
Low Forecast$-3.13B$1.60B$1.74B$717.12M$345.89M$1.56B$2.10B$2.62B$2.58B
Surprise %-92.72%-28.88%-76.49%------

INCY Forecast FAQ

Is Incyte stock a buy?

Incyte stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Incyte is a favorable investment for most analysts.

What is Incyte's price target?

Incyte's price target, set by 21 Wall Street analysts, averages $95.38 over the next 12 months. The price target range spans from $60 at the low end to $200 at the high end, suggesting a potential 29.38% change from the previous close price of $73.72.

How does Incyte stock forecast compare to the average forecast of its sector, industry, and investment themes?

Incyte stock forecast shows a 29.38% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Incyte over the past three months?

  • January 2025: 7.41% Strong Buy, 37.04% Buy, 51.85% Hold, 0% Sell, 3.70% Strong Sell.
  • December 2024: 7.41% Strong Buy, 37.04% Buy, 51.85% Hold, 0% Sell, 3.70% Strong Sell.
  • November 2024: 16.13% Strong Buy, 38.71% Buy, 41.94% Hold, 0% Sell, 3.23% Strong Sell.

What is Incyte’s EPS forecast?

Incyte's average annual EPS forecast for its fiscal year ending in December is 1.26 for 2024, a -52.81% decrease from the reported $2.67 in 2023. The prediction for 2025 is $5.9, $7.18 for 2026, $8.78 for 2027, and $10.69 for 2028.

What is Incyte’s revenue forecast?

Incyte's average annual revenue forecast for its fiscal year ending in December is $4.2B for 2024, a 13.77% increase from the reported $3.7B in 2023. The forecast for 2025 is $4.64B, $5.05B for 2026, $5.46B for 2027, and $5.94B for 2028.

What is Incyte’s net income forecast?

For its fiscal year ending in December, Incyte's average annual net income forecast is $287.16M for 2024, reflecting a -51.95% decrease from the reported $597.6M in 2023. The projection for 2025 is $1.34B, $1.26B for 2026, $1.52B for 2027, and $2.41B for 2028.